Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: BI 695501
DRUG: Humira

Sponsor

Boehringer Ingelheim